Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
NEW YORK (Reuters Health) – As the number of African Americans in a given US county increases, the number of specialists involved in colorectal cancer care decreases, according…
NEW YORK (Reuters Health) – Survivors of Hodgkin’s lymphoma are to 2- to 3-times more likely to experience a stroke or TIA compared with people in the general…
NEW YORK (Reuters Health) – Even a short period of 4 to 8 weeks of smoking cessation prior to surgery to treat upper aerodigestive tract squamous cell carcinoma…
NEW YORK (Reuters Health) – Statin therapy is associated with a reduced risk of hepatocellular carcinoma in patients with diabetes, according to a report in the June issue…
NEW YORK (Reuters Health) – Treatment of prostate cancer with androgen deprivation therapy is associated with an excess risk of incident diabetes and fractures, but not MI or…
Joe Minniti, the Executive Director of the Cancer Foundation for Personal Appearance and Larry Cohen, Executive Vice President of the NIA Group, talk about the NIA group’s support…
Michael Banks, MD, provides an overview of diffuse brainstem gliomas. This video is dedicated to the memory of Max Scotti. About Making Headway Foundation Making Headway® is a…
NEW YORK (Reuters Health) – Initiating second-line chemotherapy for ovarian cancer recurrence based on an increase in the tumor marker CA125 alone does not improve overall survival compared…
NEW YORK (Reuters Health) – Most patients with synchronous metastatic (stage IV) colorectal cancer can forgo surgery to remove the primary tumor, at least initially, opting instead for…
NEW YORK (Reuters Health) – Rituximab (Rituxan) has been implicated in 57 cases of progressive multifocal leukoencephalopathy (PML) in HIV-negative patients diagnosed with hematologic malignancies or autoimmune diseases,…
